MIST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Milestone Pharmaceuticals Inc (MIST) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The recent FDA approval of Cardamyst, along with multiple analyst upgrades and increased price targets, indicates strong potential for future growth. Despite weak financials, the positive sentiment, clean product label, and upcoming commercial launch make this a compelling opportunity for long-term gains.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 44.196, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 1.63, and resistance is at 1.806. The stock is currently trading near its pivot level of 1.718, suggesting limited immediate downside risk.
FDA approval of Cardamyst for PSVT treatment with a clean label and no market-limiting warnings.
Analysts have raised price targets to $8 and upgraded the stock to Buy, citing robust commercial potential.
Cardamyst's launch strategy and retail availability in Q1 2026 are expected to drive momentum.
Weak financial performance with negative net income (-$11.92M) and declining EPS (-14.29% YoY).
Bearish moving averages suggest caution in the short term.
Lack of recent news or congress trading data to further validate sentiment.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$11.92M (improved by 26.31% YoY), and a decline in EPS to -0.12 (-14.29% YoY). Gross margin remained at 0%.
Analysts are highly positive, with Wells Fargo, H.C. Wainwright, and TD Cowen raising price targets to $8 and upgrading the stock to Buy or Overweight. They cite Cardamyst's approval, clean label, and commercial potential as key drivers of future growth.
